🇺🇸 FDA
Pipeline program

TGR-1202

UTX-TGR-501

Phase 2 small_molecule terminated

Quick answer

TGR-1202 for Chronic Lymphocytic Leukemia is a Phase 2 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
TG THERAPEUTICS, INC.
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials